The market is paying $16 billion for a ring. Not a diamond ring. A titanium circle with sensors that tracks your sleep. Oura's planned IPO, targeting up to $3 billion, is the latest signal that consumer health tech has entered a new valuation atmosphere.
But strip away the headlines, and the real story isn't the hardware. It's the subscription revenue hiding inside. The code doesn't lie, but it does hide. In this case, it's hiding inside a recurring $5.99 monthly fee.
Context: The Market Structure
Oura has established itself as the category king in smart rings. Not a challenger. The incumbent. With over 2.5 million units sold and a valuation north of $16 billion, it sits comfortably ahead of Samsung's Galaxy Ring and the emerging Chinese brands like RingConn. The product price points range from $299 to $499, with a subscription service that adds $5.99 per month.
This is not a crypto trade. But the structural dynamics are identical. A narrative is driving valuation. In this case, the narrative is 'preventive health management' โ the shift from treating disease to optimizing wellness. The market is paying for data, not jewelry.
The IPO will likely see insiders sell a chunk of shares while the company raises fresh capital. That mix tells you something. The existing investors see a window to partially exit at a premium. The company sees a window to bank capital for expansion. Both are rational. Neither is a strong bullish signal in itself. Volatility is the tax on uncertainty. An IPO is the market's way of price discovery.
Core: The Data is the Asset, Not the Ring
When I analyzed the DeFi protocols in 2020, I learned to separate the token from the protocol. The token was a claim on future utility. The protocol was the actual system generating value. The same logic applies here.
The ring is a data-collection device. It tracks heart rate, sleep stages, body temperature, and activity. The data is then fed into a subscription service that provides analysis and insights. The real business model is not selling a $399 gadget. It's building a recurring revenue stream from health data.
This is where the technical analysis begins.
The global smart ring penetration rate is less than 1%, compared to 20% for smartwatches. That's a massive runway. But it also means the market is still in the education phase. Oura is not just selling a product; it's selling a category. That is expensive.
The subscription model is the hidden alpha. If Oura can convert even 30% of its installed base to the $5.99 monthly plan, that's roughly $60 million in recurring revenue annually from 2.5 million users. Scale that to 10 million users, and the recurring revenue stream becomes a $180 million+
But there's a catch. The data is only as good as the sensor. And the sensor is only as good as the supply chain. Oura outsources manufacturing. If the cost of raw materials or logistics spikes, the hardware margins shrink. The code does not lie, but it does hide. In this case, it hides the supply chain complexity.
I've audited smart contract code where a small bug in the fee logic would drain a pool. The equivalent here is a bug in the manufacturing line or a misjudgment in size distribution. One bad batch of rings could destroy the brand's credibility.
The Contrarian Angle: The Valuation is Priced for Perfection
Here's where I get skeptical. $16 billion is not a small number. Let's reverse-engineer it.
If Oura trades at a 10x revenue multiple (common for high-growth hardware), the market is implying roughly $1.6 billion in revenue. That's a significant leap from where it is. It suggests the market expects Oura to be a company with a $2-3 billion revenue run rate by 2027 or so. That's not an unreasonable target if the smart ring category truly scales to the size of the smart watch market. But it's also not a guarantee.
The problem is the competition.
Samsung has already entered with the Galaxy Ring, priced similarly. Apple is rumored to be working on its own ring. The tech giants have one thing Oura doesn't: distribution. They can put the product in front of millions of consumers instantly through their retail channels and existing ecosystems. Oura's advantage is its data. But data is not a moat if the big guys have the same sensors.
Also, the consumer is facing a new reality. Inflation is sticky, and the high-income segment is stable. But the Giga lower end is squeezed. If a recession hits, a $399 health accessory is a luxury, not a necessity. Yield is never free; it is rented. And the yield on the 'preventive health' thesis is rented from the disposable income of the middle class.
Takeaway: The Signal to Watch
The IPO is not the end. It's the beginning of a new phase. Watch the S-1 filing for the subscription user count and churn rate. That will tell you if the business model is a flywheel or a leaky bucket. Watch the breakdown of US vs. international revenue. That will tell you if the growth is global or dependent on the US market.
The key signal will be the post-IPO pricing. If the stock trades up and stabilizes, the market is endorsing the health data narrative. If it falls below the listing price, the market is saying the $16 billion valuation was over-cooked.
As a trader, I'm not buying the ring. I'm watching the data. The code doesn't lie, but it does hide. The next earnings report will show what it's hiding.
